13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001444043
Total reported value
$1.1B
$1.1B
37 檔
159.4%
According to the latest 13F quarterly dataset, Camber Capital Management LP managed an equity portfolio of $1.1B at the end of Q2 2024, spanning 37 distinct U.S. exchange-listed positions.
During Q2 2024, Camber Capital Management LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 26.36% | — | -20.45% | |
| 2 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 5.78% | — | — | |
| 3 | BAX | Baxter International Inc | Stock-Healthcare | 5.09% | — | +10.00% | |
| 4 | MDT | Medtronic plc | Stock-Healthcare | 4.90% | — | +21.62% | |
| 5 | UHS | Universal Health Services-b | Stock-Healthcare | 4.86% | — | -24.00% | |
| 6 | GMED | Globus Medical Inc - A | Stock-Healthcare | 4.74% | — | — | |
| 7 | VTRS | Viatris Inc | Stock-Healthcare | 4.41% | — | -7.69% | |
| 8 | HUM | Humana Inc | Stock-Healthcare | 4.14% | — | — | |
| 9 | MYGN | Myriad Genetics Inc | Stock-Other | 3.72% | — | -27.96% | |
| 10 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 3.40% | — | — | |
| 11 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 2.96% | — | -12.50% | |
| 12 | BKD | Brookdale Senior Living Inc | Stock-Other | 2.93% | — | — | |
| 13 | GSK | Gsk Plc-spon Adr | Stock-Healthcare | 2.85% | — | +22.99% | |
| 14 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 2.51% | — | +340.00% | |
| 15 | SEM | Select Medical Holdings CORP | Stock-Other | 2.47% | — | -25.00% | |
| 16 | CVS | Cvs Health CORP | Stock-Healthcare | 2.45% | — | — | |
| 17 | WBA | Walgreens Boots Alliance Inc | Stock-Other | 2.34% | — | -10.26% | |
| 18 | PFE | Pfizer Inc | Stock-Healthcare | 1.94% | — | — | |
| 19 | QGEN | Qiagen N.V. | Stock-Healthcare | 1.71% | — | +23.97% | |
| 20 | ZIMV | Zimvie Inc | Stock-Other | 1.64% | — | — | |
| 21 | DNLI | Denali Therapeutics Inc | Stock-Other | 1.29% | — | +33.33% | |
| 22 | PRGO | Perrigo Company plc | Stock-Healthcare | 1.08% | — | — | |
| 23 | HLF | Herbalife Ltd. | Stock-Other | 0.86% | — | — | |
| 24 | ARGX | Argenx Se - Adr | Stock-Healthcare | 0.86% | — | — | |
| 25 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.66% | — | -74.36% | |
| 26 | BKD 7 11-15-25Bond | Brookdale Senior Living | Bond | 0.64% | — | — | |
| 27 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.51% | — | +103.33% | |
| 28 | OSUR | Orasure Technologies Inc | Stock-Other | 0.50% | — | — | |
| 29 | INGN | Inogen Inc | Stock-Other | 0.45% | — | — | |
| 30 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.43% | — | — | |
| 31 | ANAB | Anaptysbio Inc | Stock-Other | 0.35% | — | — | |
| 32 | REPL | Replimune Group Inc | Stock-Other | 0.34% | — | -50.91% | |
| 33 | EVH | Evolent Health Inc - A | Stock-Other | 0.33% | — | — | |
| 34 | TBPH | Theravance Biopharma, Inc. | Stock-Other | 0.23% | — | — | |
| 35 | SKIN | Skinhealth Systems Inc | Stock-Other | 0.19% | — | — | |
| 36 | ✓ | Curevac N V | Stock-Other | 0.05% | — | -68.57% | |
| 37 | GMAB | Genmab A/s -sp Adr | Stock-Other | 0.03% | — | — |
According to official SEC Form 13F filings, Camber Capital Management LP reported a total U.S. public equity portfolio value of $1.1B across 37 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SPY, ZBH, BAX) accounted for 159.4% of total reported equity market value during Q2 2024.
During Q2 2024, Camber Capital Management LP's top holdings by market value included SPY (26.4%)、ZBH (5.8%)、BAX (5.1%). The largest single position, SPY, represented 26.4% of total portfolio value.
In Q2 2024, Camber Capital Management LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.